Astrana Health (NASDAQ:ASTH) Rating Increased to Hold at Macquarie

Macquarie upgraded shares of Astrana Health (NASDAQ:ASTH) to a hold rating in a research report sent to investors on Monday,Zacks.com reports.

A number of other research analysts have also recently commented on the company. TD Cowen assumed coverage on Astrana Health in a research note on Monday, October 14th. They issued a “buy” rating and a $66.00 target price on the stock. KeyCorp assumed coverage on Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. Robert W. Baird upped their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, BTIG Research lifted their price target on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Astrana Health currently has an average rating of “Moderate Buy” and an average price target of $65.17.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $35.52 on Monday. The stock has a market cap of $2.00 billion, a P/E ratio of 27.32, a PEG ratio of 1.80 and a beta of 1.13. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The business’s 50-day moving average price is $49.04 and its two-hundred day moving average price is $48.12. Astrana Health has a twelve month low of $34.11 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the previous year, the business posted $0.47 earnings per share. As a group, equities analysts predict that Astrana Health will post 1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

A number of large investors have recently added to or reduced their stakes in ASTH. Central Pacific Bank Trust Division bought a new position in shares of Astrana Health during the third quarter valued at about $160,000. SG Americas Securities LLC bought a new position in Astrana Health during the 3rd quarter valued at approximately $680,000. Granite Bay Wealth Management LLC purchased a new stake in Astrana Health in the 3rd quarter worth approximately $290,000. Handelsbanken Fonder AB bought a new stake in shares of Astrana Health in the 3rd quarter worth approximately $492,000. Finally, GAMMA Investing LLC purchased a new position in shares of Astrana Health during the third quarter valued at approximately $34,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.